JP2011527575A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527575A5
JP2011527575A5 JP2011517443A JP2011517443A JP2011527575A5 JP 2011527575 A5 JP2011527575 A5 JP 2011527575A5 JP 2011517443 A JP2011517443 A JP 2011517443A JP 2011517443 A JP2011517443 A JP 2011517443A JP 2011527575 A5 JP2011527575 A5 JP 2011527575A5
Authority
JP
Japan
Prior art keywords
gene expression
level
tumor
heyl
cancer tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527575A (ja
Filing date
Publication date
Priority claimed from US12/360,790 external-priority patent/US7544476B1/en
Application filed filed Critical
Publication of JP2011527575A publication Critical patent/JP2011527575A/ja
Publication of JP2011527575A5 publication Critical patent/JP2011527575A5/ja
Pending legal-status Critical Current

Links

JP2011517443A 2008-07-11 2009-05-28 Ｎｏｔｃｈシグナル伝達のインヒビターでの処置に感受性であるがんの同定 Pending JP2011527575A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8012208P 2008-07-11 2008-07-11
US61/080,122 2008-07-11
US12/360,790 2009-01-27
US12/360,790 US7544476B1 (en) 2008-07-11 2009-01-27 Identifying cancers sensitive to treatment with inhibitors of notch signaling
PCT/US2009/045479 WO2010005644A1 (en) 2008-07-11 2009-05-28 Identifying cancers sensitive to treatment with inhibitors of notch signaling

Publications (2)

Publication Number Publication Date
JP2011527575A JP2011527575A (ja) 2011-11-04
JP2011527575A5 true JP2011527575A5 (enExample) 2012-07-12

Family

ID=40688675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517443A Pending JP2011527575A (ja) 2008-07-11 2009-05-28 Ｎｏｔｃｈシグナル伝達のインヒビターでの処置に感受性であるがんの同定

Country Status (6)

Country Link
US (1) US7544476B1 (enExample)
EP (1) EP2313526A4 (enExample)
JP (1) JP2011527575A (enExample)
AU (1) AU2009269081A1 (enExample)
CA (1) CA2730215A1 (enExample)
WO (1) WO2010005644A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540694B2 (en) * 2006-05-19 2017-01-10 The Johns Hopkins University HEYL as a therapeutic target and a diagnostic marker for neoplasia and uses therefor
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
ES2737649T3 (es) 2012-12-19 2020-01-15 Aveo Pharmaceuticals Inc Anticuerpos anti-Notch3
EP3448420B1 (en) 2016-04-29 2022-09-14 Aveo Pharmaceuticals, Inc. Anti-notch3 antibody
EP3462349A1 (en) * 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
CA2600908A1 (en) 2005-03-04 2006-09-08 The Hospital For Sick Children Methods for cancer prognosis
PL1962895T3 (pl) * 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
US9540694B2 (en) 2006-05-19 2017-01-10 The Johns Hopkins University HEYL as a therapeutic target and a diagnostic marker for neoplasia and uses therefor

Similar Documents

Publication Publication Date Title
Bonne et al. Salivary biomarker development using genomic, proteomic and metabolomic approaches
Lohaus et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Siegal et al. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab
JP2015523569A5 (enExample)
JP2016513094A5 (enExample)
Bertoli et al. Liquid biopsy in NSCLC: an investigation with multiple clinical implications
RU2017126701A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
RU2010123381A (ru) Способ и композиции для диагностического применения у раковых пациентов
NZ595993A (en) Method for diagnosis of cancer and monitoring of cancer treatments
JP2016537010A5 (enExample)
CN103608683A (zh) Hedgehog抑制剂治疗的生物标志物
JP2013500001A5 (enExample)
JP2013541339A5 (enExample)
JP2010538609A5 (enExample)
HRP20231525T1 (hr) Postupci i pripravci za dijagnozu i liječenje raka
JP2019534321A5 (enExample)
JP2015210268A5 (enExample)
JP2018527886A5 (enExample)
JP2009516178A5 (enExample)
WO2014028222A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
Puente et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
JP2013505008A5 (enExample)
WO2010085124A3 (ko) 간암진단과 재발 및 생존 예측용 마커, 이를 포함한 키트 및 상기 마커를 이용한 간암환자 예후 예측
WO2024247694A1 (ja) 悪性腫瘍の治療
Stope et al. Functionality of the tumor suppressor microRNA-1 in malignant tissue and cell line cells of uterine leiomyosarcoma